Source: Atherosclerosis. Conference titles: Congress of the European Atherosclerosis Society. Unidade: FM
Subjects: MUTAÇÃO GENÉTICA, HIPERCOLESTEROLEMIA, CORONARIOPATIA (PREVENÇÃO E CONTROLE)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAVALI, S. et al. Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin. Atherosclerosis. Amsterdam: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 05 maio 2026. , 2004APA
Cavali, S., Moretti, I., Matsumoto, L., Salazar, L., Hiroyuki, M., Forti, N. A., et al. (2004). Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin. Atherosclerosis. Amsterdam: Faculdade de Medicina, Universidade de São Paulo.NLM
Cavali S, Moretti I, Matsumoto L, Salazar L, Hiroyuki M, Forti NA, Diament J, Chiara M, Faludi A, Dominguez R. Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin. Atherosclerosis. 2004 ; 5( 1): 112.[citado 2026 maio 05 ]Vancouver
Cavali S, Moretti I, Matsumoto L, Salazar L, Hiroyuki M, Forti NA, Diament J, Chiara M, Faludi A, Dominguez R. Novel CYP3A4 gene mutations: contribution to the pharmacogenetic profile of hypercholesterolemic individuals treated with atorvastin. Atherosclerosis. 2004 ; 5( 1): 112.[citado 2026 maio 05 ]
